Samuel G. Johnson

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

Laura B. Ramsey, Samuel G. Johnson, Kelly E. Caudle et al. · Clinical Pharmacology & Therapeutics · 2014 · 437 citations · Full text

Slco1b1 Genotype, Lipid Disorder, Cardiovascular Disease +13

Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process

Kelly E. Caudle, Teri E. Klein, James M. Hoffman et al. · Current Drug Metabolism · 2014 · 423 citations · Full text

Genetic Epidemiology, Pharmacotherapy, Genetic Medicine +18

The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

Russell A. Wilke, Laura B. Ramsey, Samuel G. Johnson et al. · Clinical Pharmacology & Therapeutics · 2012 · 324 citations · Full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-α–Based Regimens

Andrew J. Muir, Li Gong, Samuel G. Johnson et al. · Clinical Pharmacology & Therapeutics · 2013 · 92 citations · Full text

Rbv Therapy, Immunodeficiencies, Genetic Epidemiology +27

Outcomes Associated With Combined Antiplatelet and Anticoagulant Therapy

Samuel G. Johnson, Kristina Rogers, Thomas Delate et al. · CHEST Journal · 2008 · 80 citations

Thrombosis, Cardiovascular Disease, Combined Antiplatelet +7